Equities Analysts Offer Predictions for CEL-SCI Co.’s Q2 2024 Earnings (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM) – Zacks Small Cap issued their Q2 2024 earnings per share (EPS) estimates for CEL-SCI in a report issued on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten expects that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for CEL-SCI’s current full-year earnings is ($0.48) per share. Zacks Small Cap also issued estimates for CEL-SCI’s Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.11) EPS and FY2026 earnings at ($0.24) EPS.

CEL-SCI (NYSE:CVM) last posted its earnings results on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter.

Separately, StockNews.com downgraded CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

CEL-SCI Price Performance

NYSE:CVM opened at $1.50 on Tuesday. CEL-SCI has a 52 week low of $1.04 and a 52 week high of $3.23. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $80.97 million, a P/E ratio of -2.21 and a beta of 1.29. The stock’s fifty day moving average is $2.03 and its two-hundred day moving average is $2.18.

Institutional Investors Weigh In On CEL-SCI

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new stake in shares of CEL-SCI in the fourth quarter valued at $26,000. MML Investors Services LLC acquired a new stake in shares of CEL-SCI in the third quarter valued at $31,000. BNP Paribas Arbitrage SA grew its stake in shares of CEL-SCI by 195.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,280 shares of the company’s stock valued at $37,000 after buying an additional 5,474 shares in the last quarter. FMR LLC grew its stake in shares of CEL-SCI by 1,061.5% in the second quarter. FMR LLC now owns 9,385 shares of the company’s stock valued at $42,000 after buying an additional 8,577 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of CEL-SCI by 2,011.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 16,198 shares of the company’s stock valued at $44,000 after buying an additional 15,431 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.